OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	337
Vertical integration in oncology: what does it mean for patients with cancer?	208
Re: Deng and Heybati	147
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	134
The Unrelenting Impact of Poverty on Cancer: Structural Inequities Call for Research and Solutions on Structural Determinants	132
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	132
The National Cancer Institute Funding of Global Research: Lessons Learned and Opportunities Going Forward	127
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	123
Response to Liu and Zhang	117
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	116
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	106
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	87
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination	71
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	69
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	65
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Active Lifestyle Study	65
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	63
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	62
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	61
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	61
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	57
Li-Fraumeni Syndrome in the Cancer Genomics Era	55
Understanding risk factors for endometrial cancer in young women	52
Long-term aspirin use and cancer risk: a 20-year cohort study	51
Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	51

Medication–Associated Phthalate Exposure and Childhood Cancer Incidence	51
RE: Use of artificial intelligence for cancer clinical trial enrollment	50
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America	47
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	47
Treatment deescalation for older women with favorable breast cancers: patient values and shared decision making	46
Association Between Medicaid Expansion Under the Affordable Care Act and Survival Among Newly Diagnosed Cancer Patients	45
Determinants of late metastases in renal cell carcinoma	45
Behavioral Research in Cancer Prevention and Control: Emerging Challenges and Opportunities	45
Patients’ attitudes and preferences toward delayed disease progression in the absence of improved survival	44
Cancer control co-benefits of the climate-related provisions in the American Inflation Reduction Act	44
Evaluating colonoscopy quality by performing provider type	44
RE: Prevalence of cancer survivors in the United States	43
Correction to: Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study	42
Optimizing public-private partnerships to support clinical cancer research	42
Premature aging as an accumulation of deficits in young adult survivors of pediatric cancer	42
RE: Autoimmune disease and the risk of anal cancer in the US elderly population	41
Health-related quality of life by race, ethnicity, and country of origin among cancer survivors	41
Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas	41
Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors	41